Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

plastic_CRC Targeting Tumour Cell Plasticity in Colorectal Cancer

Coordinator
Fundacio Institut De Recerca Biomedica (irb Barcelona), Spain
Runs
1 September 2026 to 31 August 2031
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101268092

What the project is doing

In the project's own words, from its summary on CORDIS.

Most cancer therapies target cell-intrinsic alterations or aim to boost immune-mediated cytotoxicity. Despite vast efforts, these strategies have not prevented or cured metastatic colorectal cancer (mCRC). A novel approach is needed. We propose to exploit a therapeutic target space revealed from the analysis of transcriptional plasticity. We will identify therapeutic drugs that treat plasticity not as a liability but as a tool to induce susceptibility.

Objective 1 aims to develop a new classification of CRC based on intratumor heterogeneity (ITH): by single-cell and spatial transcriptomics, we will define common transcriptional programs and build a catalog of tumor cell state archetypes. We will then link ITH subtypes with clinical outcomes. Objective 2 searches for drugs (~2,400, mostly FDA-approved) that control plasticity: a pooled single-cell screen in PDOs representing the main ITH CRC subtypes will quantify drug-induced state shifts and nominate agents that constrain heterogeneity, generating second-hit–vulnerable states.

Objective 3 will evaluate rational treatment combinations that would first reprogram composition through targeted manipulation of plasticity and then eradicate the induced vulnerable state. We will test efficacy of these novel strategies in minimal-residual-disease and overt liver metastasis preclinical CRC models. In Objective 4 we will exploit the phenotypic atlas of drug-induced reprogramming to validate mechanistic hypotheses using genetic approaches, defining key regulators of transcriptional plasticity.

Together, we will establish a precision-oncology paradigm centered on targeting plasticity for mCRC. We expect to deliver at least one proof of principle therapeutic strategy tailored to each ITH CRC subtype, exploiting rational drug sequences that leverage plasticity as a vulnerability. Because our screening library emphasizes repurposable drugs, prioritized combinations will be well positioned for medium term clinical evaluation.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Recerca Biomedica (irb Barcelona)BarcelonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI